Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone

Phase 1/2 Completed 126 enrolled Xiangya Hospital of Central South University

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of sublingual naloxone in the treatment of chronic itch in patients under arsenic exposure.

Timeline

Start: 2019-02-13
Primary completion: 2019-03-01
Completion: 2019-03-30

Publications

Background Xiao Y, Huang X, Jing D, Huang Y, Zhang X, Shu Z, Huang Z, Su J, Li J, Zhang J, Chen M, Chen X, Shen M. Assessment of the Dermatology Life Quality Index (DLQI) in a homogeneous population under lifetime arsenic exposure. Qual Life Res. 2018 Dec;27(12):3209-3215. doi: 10.1007/s11136-018-1969-2. Epub 2018 Sep 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naloxone	Small molecule	0.4 mg	Subcutaneous

Indications

No indication recorded.